Market Brief: Orthobiologics Market Will See Modest Growth By 2024, Stimulated By Growth Factors
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
You may also be interested in...
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.
Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.